Investor Alert

New York Markets Open in:

Market Pulse Archives

March 8, 2018, 8:34 a.m. EST

BioScrip accounting review identifies 'internal control deficiencies' and 'material weakness'

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore


BioScrip Inc. said Thursday that after a review of financial statements, it identified "internal control deficiencies" that may have led to potential financial statement errors. The stock edged up 0.3% in premarket trade. The deficiencies were in connection with reconciliations for certain asset and liability accounts. The provider of infusion and home care management services said the potential errors do not appear to be material, but the ongoing review may result in a delay in the filing of its Form 10-K annual report with the Securities and Exchange Commission. The company said it will report a "material weakness" related to certain spreadsheets used to calculate periodic adjustments to accounts, but it did not have any effect on 2017 financial statements. Separately, the company reported a fourth-quarter net loss that narrowed to $1.2 million from $5.2 million a year ago, and revenue of $182.6 million. The stock has run up 17.6% over the past three months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.46% has gained 2.8%.

-20.49 -0.46%
Volume: 2.32B
Aug. 4, 2021 4:55p

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.